Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Nuwellis Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.5 (market cap $16.72B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 7600× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 3,963,319). Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Nuwellis Inc for 26 Days on average.
| IEI | NUWE | |
|---|---|---|
Market Cap | $16.72B | $2.20M |
Volume | 3,963,319 | 121,544 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $146.65 |
52-Week Low | $113.17 | $0.68 |
Typical Hold Time | 43 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.49 with minimal daily movement, up 0.1%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent corporate actions include consistent dividend payments. The bond market environment, highlighted by rising Treasury yields, influences sentiment, with news pointing to volatility in interest rates affecting fixed-income related assets.
The outlook remains cautious due to bearish technical signals and macroeconomic pressures from rising yields. Investment opportunities include dividend consistency, but risks involve interest rate sensitivity and market volatility. A neutral to bearish stance is warranted pending clearer fundamental data or stabilization in bond markets.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
